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Objectives: To examine the link between increased body mass index and benign prostatic hyperplasia (BPH)
related complications, namely: acute urinary retention (AUR), Bladder stones and Bladder diverticula.
Material and methods: Patients: We reviewed the medical records of BPH patients who underwent prostatectomy
over three years period from 2010–2012. Prostatectomy was either done in the gold standard transurethral
resection of the prostate (TURP) or using green light laser selective photo-vaporization (PVP). Age, PSA, Prostate
Volume (PV) as measured by ultrasonography, patients’ weight & height, BPH related complications mainly AUR,
bladder stones, and bladder diverticula were all taken in account. The BMI was calculated as weight in kg divided
by square height in meters. The BMI was divided in 4 categories according to WHO classification: underweight if BMI
≤18.50 kg/m2; normal weight if BMI = 18.50-24.9 kg/m2; overweight: BMI ≥25 kg/m2; and obese BMI if ≥30 kg/m2. Statistical
analysis: done using the SPSS package version 16. Chi-square test was used for comparison between groups where
p-value was considered significant if <0.05 and ANOVA test was used for comparison between multiple variables.
Results: 197 patients were included in this study, of those 95(48%) underwent TURP and 102(52%) underwent PVP. The two
groups were found to be similar in mean age and PSA, and significantly different in prostate volume and operating room
(O.R.) time.
Conclusions: Although the mean weight for patients undergoing prostatectomy in this study was in the
overweight range, yet only 59/197(30%) patients with increased BMI presented with AUR. In this particular
cohort of patients undergoing prostatectomy there was no significant differences in the development of AUR,
bladder stone and diverticulum formation between patients with increased BMI (overweight and obese) and
those with normal BMI. Further studies are recommended to explore the influence of increased BMI on
BPH-related complications.Introduction
Obesity has recently been declared to be associated with
several urological diseases (Hammarsten et al. 1998).
Central obesity and lack of physical exercise were placed
among the top risk factors for the development of BPH
(Hammarsten et al. 1998; Hammarsten & Högstedt
1999; Hammarsten & Högstedt 2001; Hammarsten &
Högstedt 2002; Hammarsten et al. 2009). It has been
shown in the placebo arm of Reduce® study that the
prostatic growth is accelerated in overweight and obese* Correspondence: hmosli@hotmail.com
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in any medium, provided the original work is ppatients while in the treatment arm the response to
treatment with 5-alpha reductase enzyme inhibitors was
attenuated in those patients (Kaplan & Wilson 2007;
Muller et al. 2012). It is therefore assumed that
increased BMI is linked to increased prostate sizes in patients
undergoing surgical treatment namely prostatectomy
and when examining the BPH-related complications
such as retention of urine (AUR), bladder stone and
diverticulum formation, we anticipated that these complica-
tions were higher in overweight and obese patients than in
normal weight patients undergoing prostatectomy.is an open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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The objective of this study was to examine the link
between increased BMI and BPH related complications.
Those complications examined were: AUR, Bladder stones
and Bladder diverticula.Material and methods
Patients
We reviewed the medical records of BPH patients who
underwent prostatectomy over three years period from
2010–2012. Prostatectomy was either done in the gold
standard transurethral resection of the prostate (TURP)
or using green light laser selective photo-vaporization
(PVP). Age, PSA, Prostate Volume (PV) as measured by
ultrasonography, patients’ weight & height, BPH related
complications mainly AUR, bladder stones, and bladder
diverticulum were all taken in account. The BMI was
calculated as weight in kg ÷ square height in meter. The
BMI was divided in 4 categories according to WHO
classification: underweight if BMI ≤18.50 kg/m2; nor-
mal weight if BMI = 18.50-24.9 kg/m2; overweight:
BMI ≥25 kg/m2; and obese BMI if ≥30 kg/m2. All
participants signed an informed consent prior to
inclusion in the study. The study was approved by
the Institution’s Unit of Biomedical Ethics- Research
Committee.
Statistical Analysis: Was done using the SPSS package
version 16. Chi-square test was used for comparison
between groups where p-value was considered signifi-
cant if <0.05 and ANOVA test was used for comparison
between multiple variables.Results
197 patients were included in this study, of those 95
(48%) underwent TURP and 102(52%) underwent
PVP. The two groups were found to be matched in
mean age and PSA, and significantly different in
prostate volume and operating room (O.R.) time. The
results are summarized in Tables 1, 2, 3, 4 and 5.












*significant using chi-square test at 0.05 level.undergoing TURP, 38 (40%, 19.2% of total study
population) were in the underweight-normal BMI
group, whereas 67 (60%, 28.8% of total study popula-
tion) were in the overweight-obese BMI group. Of
the 102 patients undergoing PVP, BMI data was
available for 77 patients. Analysis of this data showed
that 34 (44.15%) were in the underweight-normal
BMI group, and 43 (55.85%) were in the overweight-obese
BMI group.Discussion
Evidence elicited from the current study did not demon-
strate an increase in the risk of developing BPH-related
complications with an increased BMI. No significant
differences were noted in the development of AUR,
bladder stone and diverticulum formation; between
patients with increased BMI (overweight and obese)
and those with normal BMI. A relationship between
higher BMIs and elevated PSA, poorer uroflow,
increased incidence of retention, and larger prostate
volume were expected to be seen, however our study
demonstrated a relationship that was NOT statistically
significant.
The metabolic syndrome is common in Arabian Gulf
countries especially Saudi Arabia. It comprises a number
of disorders—including insulin resistance, hypertension
and central abdominal obesity—that all act as risk
factors for cardiovascular diseases. Accumulating
evidence now exists to link urological diseases to the
metabolic syndrome (Hammarsten et al. 1998). Most
established aspects of the metabolic syndrome are prima-
rily linked to benign prostatic hyperplasia (BPH) and
prostate cancer (Hammarsten et al. 1998; Hammarsten &
Högstedt 1999; Hammarsten & Högstedt 2001; Hammarsten
& Högstedt 2002; Hammarsten et al. 2009). Fasting
plasma insulin, in particular, was linked to BPH and
all subtypes of prostate cancer namely: incidental,
aggressive and lethal prostate cancer (Hammarsten &
Högstedt 2002). Medical treatment is thought to be








Table 2 Showing the similarities and differences between
the study’s prostatectomy groups
Group N Mean Std. Deviation P-value
Age
TURP 95 68.36 8.67
0.020
PVP 121 71.24 9.07
O.R. time
TURP 95 86.48 37.56
<0.0001
PVP 79 61.12 40.38
Prostate volume
TURP 95 60.95 33.32
<0.0001
PVP 101 46.93 14.30
PSA
TURP 94 9.17 39.00
.262
PVP 100 4.71 6.58
Abbreviations: TURP transurethral resection of the prostate, PVP photo-selective
vaporization of the prostate, O.R. operative room, PSA prostate
specific antigen.
Table 4 Showing the data for the whole cohort
Age
Minimum 51 Mean 68.3684 years
Maximum 90 years standard deviation 8.67
PSA
Minimum 00.00 Mean 6.87 ng/ml
Maximum 373.00 standard deviation 27.57
PV
Minimum 15 Mean 54.11





Maximum 38.28 standard deviation 4.39
AUR 74 /197 37.6%
Bladder stones 17/180 8.6%
Diverticulum 3/194 1.5%
Abbreviations: PSA prostate specific antigen, PV prostate volume, BMI body
mass index, AUR acute retention of urine.
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Overall, the results of studies on urological aspects of
the metabolic syndrome seem to indicate that BPH
and prostate cancer are recently considered as two
aspects of the metabolic syndrome, and that an in-
creased insulin level is a common underlying aberra-
tion that promotes both BPH and clinical prostate
cancer (Nandeesha et al. 2006).
Affluence associated with prosperity in wealthy
countries has resulted in some serious health prob-
lems due to overindulgence in the consumption of
high calorie foods and sugar sweetened beverages,
and intake of excessive amounts of fast and fatty
food. Obesity follows with all its sequences, especially
when living a sedentary life and lack of protective
regular physical activities against cardiovascular dis-
eases (Guo et al. 2005).
The main concern with the metabolic syndrome is the
cardiovascular diseases, mainly coronary artery disease
(CAD) as this is a leading cause of death. Furthermore,
an association between benign prostatic hyperplasia and
primary hypertension was reported (Guo et al. 2005).
The relationships between body mass index and








Data Not available 25 12.69
Total 197 100.0The links of central obesity and lack of physical exer-
cise to some medical conditions are all illustrated in
Figure 1.
Obesity is measured by several methods, but for
practical purposes and simplicity, it is represented in
clinical urology by WC or BMI (Hammarsten &
Högstedt 1999). Recent data suggested a relationship
between the WC and health parameters, mainly dia-
betes, hypertension, prostate volume (PV), voiding
and sexual dysfunction (Hammarsten & Högstedt
1999).Diabetes mellitus has been extensively discussed
as a risk factor for many urological disorders, mainly
voiding and sexual dysfunction (Ochiai et al. 2005; Li
et al. 2005). Furthermore, there is evidence that type
2 diabetes mellitus is associated to, linked to, or even
a direct sequel of obesity through the development of
insulin resistance (Parsons et al. 2006).The resultant
hyperinsulinemia (Parsons et al. 2009; Ozden et al.
2007; Keto et al. 2011; De Nunzio et al. 2012) plays a
major role in the pathophysiological changes that
occur in the genitourinary system and throughout the
whole human body as shown in Figure 1.
Evidence from a large prospective study indicates that
a progressive increase in the BMI is associated with pro-
gressive increase in PV and attenuated response to
treatment with 5-alpha reductase inhibitors (Kaplan &
Wilson 2007; Muller et al. 2012; Lee et al. 2011;
Roehrborn et al. 2006). In our opinion this finding
has an important relevant therapeutic implication in
the medical treatment of obese men with BPH. This
also warrants further research studies on the relation-
ship between the degree of obesity and unresponsive-
ness to medical therapy and the development of
complications of BPH such as retention of urine,
bladder stones and diverticula formation.
Table 5 Showing influence of BMI on BPH-related complications
Group DIVERTICULUM Total RETENTION Total BLADDER STONE Total
Absence Present Absence Present Absence Present
TURP Normal Count 37 1* 38 22 16** 38 33 5*** 38
% 97.40% 2.60% 100.00% 57.90% 42.10% 100.00% 86.80% 13.20% 100.00%
Overweight & Obese Count 55 2* 57 33 24** 57 47 10*** 57
% 96.50% 3.50% 100.00% 57.90% 42.10% 100.00% 82.50% 17.50% 100.00%
Count 92 3 95 55 40 95 80 15 95
% 96.80% 3.20% 100.00% 57.90% 42.10% 100.00% 84.20% 15.80% 100.00%
PVP Normal Count 28 28 15 13**** 28 28 0***** 28
% 100.00% - 100.00% 53.60% 46.40% 100.00% 100.00% 0.00% 100.00%
Overweight & Obese Count 37 37 31 6**** 37 36 1***** 37
% 100.00% - 100.00% 83.80% 16.20% 100.00% 97.30% 2.70% 100.00%
Count 65 65 46 19 65 64 1 65
% 100.00% - 100.00% 70.80% 29.20% 100.00% 98.50% 1.50% 100.00%
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Although the mean weight for patients undergoing
prostatectomy in this study was in the overweight
range, yet only 59/197(30%) patients with increased
BMI presented with AUR. In this particular cohort of
patients undergoing prostatectomy there was no sig-
nificant differences in the development of AUR, blad-
der stone and diverticulum formation between
patients with increased BMI (overweight and obese)Figure 1 Illustrating the links between Obesity and affected health paand those with normal BMI. Further studies are
recommended to explore the influence of increased
BMI on BPH-related complications. Subsequently,
active life style and weight reduction can be discussed with
patients with symptomatic BPH within the context
of benefit not only in improving LUTS, and slowing
the growth of the prostate but also to improve re-
sponse to medical therapy and prevent BPH related
complications.rameters.
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